GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer: Immune results, by Emmanuel S. Antonarakis, MD, et al

ORLANDO, FL, USA (UroToday.com) - Sipuleucel-T is an autologous cellular immunotherapy that targets prostatic acid phosphatase (PAP) and is FDA-approved for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing of ADT and sipuleucel-T to maximize immune and clinical responses is unknown.

Here, we report interim data from a phase 2 trial evaluating the sequencing of sipuleucel-T and ADT by examining immune parameters in patients with BRPC at high risk for metastases...Click here to enlarge and view the poster.

 
                                (Click thumbnail to enlarge poster)

Read session highlights by a UroToday.com medical editor

Presented by Emmanuel S. Antonarakis,¹ Adam S. Kibel,² Robert C. Tyler,³ Candice McCoy,³ Yang Wang,³ Nadeem A. Sheikh,³ and Charles G. Drake¹ at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; ²Dana-Farber Cancer Institute, Boston, MA; ³Dendreon Corporation, Seattle, WA

View Full 2013 GU Cancers Symposium Coverage